Comparison of molecular serotyping approaches of *Streptococcus agalactiae* from genomic sequences

Georgia Kapatai 1*, Darshana Patel 2, Androulla Efstratiou 2 and Victoria J. Chalker 1

**Abstract**

**Background:** Group B streptococcus (GBS) capsular polysaccharide is one of the major virulence factors underlying invasive GBS disease and a component of forthcoming vaccines. Serotype classification of GBS is based on the capsule polysaccharide of which ten variants are known to exist (Ia, Ib, II-IX). Current methods for GBS serotype assignment rely on latex agglutination or PCR while more recently a whole genome sequencing method was reported. In this study, three distinct algorithms for serotype assignment from genomic data were assessed using a panel of 790 clinical isolates.

**Methods:** The first approach utilised the entire capsular locus coupled with a mapping methodology. The second approach continues from the first and utilised a SNP-based methodology across the conserved *cpsD-G* region to differentiate serotypes Ia-VII and IX. Finally the third approach used the variable *cpsG-K* region coupled with a mapping methodology. All three approaches were assessed for typeability (percentage of isolates assigned a serotype) and concordance to the latex agglutination methodology.

**Results:** Following comparisons, the third approach using the variable *cpsG-K* region demonstrated the best performance with 99.9% typeability and 86.7% concordance. Overall, of the 105 discordant isolates, 71 were resolved following retesting of latex agglutination and whole genome sequencing, 20 failed to assign a serotype using latex agglutination and only 14 were found to be truly discordant on re-testing. Comparison of this final approach with the previously described assembly-based approach returned identical results.

**Conclusions:** These results demonstrated that molecular capsular typing using whole genome sequencing and a mapping-based approach is a viable alternative to the traditional, latex agglutination-based serotyping method and can be implemented in a public health microbiology setting.

**Keywords:** Group B Streptococci, Serotyping, Whole genome sequencing, *Streptococcus agalactiae*
important particularly for assessing serotype distributions in vaccine coverage and post-vaccine surveillance studies.

The capsular polysaccharide is encoded on the \textit{cps} locus and is composed of 16-18 genes \[8\]. The \textit{cpsA} to \textit{-F} genes are located at one end distal to the \textit{cpsL}, NeuB, \textit{-D}, \textit{-A} and \textit{-C} genes at the other, and these genes are highly conserved across the ten serotypes. In the central region from \textit{cpsG} to \textit{-K} in serotypes Ia-VII and IX and from \textit{cpsR} to \textit{-K} for serotype VIII the presence of genes and/or the sequence similarity varies between the serotypes (Fig. 1).

Multiple phenotypic serotyping methods such as latex agglutination, enzyme-based immunoassays and flow cytometry experiments using anti-capsular monoclonal antibodies have been described for GBS \[9–11\]. These assays can have limited typeability, can be subjective and are not able to assign all isolates to a type resulting in a high number of non-typeable isolates. Genotypic methods such as PCR-based DNA hybridisation, real-time PCR and restriction fragment length polymorphism assays can identify genetic variants in the \textit{cps} locus that can be used to assign isolates to a serotype \[12–15\].

With the continuous reduction in cost of whole-genome sequencing (WGS) and the rapid development of bioinformatic infrastructures to analyse and store the large amount of data generated, WGS can provide a feasible approach to perform GBS serotyping. A recent study has described an approach to successfully determine the GBS serotype from WGS data \[16\]. The approach used was based on differences in the variable region of the \textit{cps} locus and was able to assign isolates to all ten serotypes with high concordance with previous typing methods. In this study we sought to develop, compare and validate multiple WGS-based serotyping assays for GBS to determine the optimal methodology for implementation into a public health reference microbiology laboratory.

\textbf{Methods}

\textbf{GBS reference strains and clinical isolates}

A panel of 10 GBS reference strains (serotypes Ia to IX; Additional file 1: Table S1) were available from the archives of the Public Health England (PHE) Reference Laboratory.

The clinical isolates included in the study include isolates referred to the reference laboratory between April 2014 and December 2015 as well as retrospective isolates from 2010 for uncommon serotypes. In total, 790
isolates were used to compare and validate the WGS-based serotyping methods.

**Serotyping using latex agglutination**
Isolates were cultured onto Columbia agar plates supplemented with horse blood (Oxoid Ltd., Hampshire, UK) and incubated aerobically at 37 °C for 24 h. Serological classification based on capsular polysaccharide types Ia, Ib and II to IX was performed using latex agglutination according to the manufacturer’s recommendations (Statens Serum Institute, Copenhagen, Denmark).

**DNA extraction and sequencing**
Strains were pre-lysed in a lysis buffer composed of 2 mg lysozyme (Sigma-Aldrich, Dorset, UK), 120 U mutanolysin (Sigma-Aldrich), 400 μg RNase A (Qiagen, Manchester, UK), 20 μL proteinase K (>600 mAUI/mL) and 15 μL of overnight culture. Cell suspensions were incubated for 1 h at 37 °C, 2 h at 56 °C followed by 1 h at 80 °C. DNA was extracted using the QIAasympy SYM SP system and the QIAasympy DSP mini kit (Qiagen) according to the manufacturer’s recommendations. DNA concentrations were measured using the Quant-iT dsDNA Broad-Range Assay Kit (Life Technologies, Paisley, UK) and GloMaxR Microplate Luminometer (Promega, Southampton, UK). For sequencing preparation, a Nextera XT DNA Library Preparation Kit (Illumina, San Diego, CA, USA) was used followed by sequencing using a HiSeq 2500 System (Illumina) and the 2 × 100-bp paired-end mode.

**Bioinformatic processing**
Casava 1.8.2 (Illumina) was used to deplex the samples and FASTQ reads were processed with Trimmomatic to remove bases from the trailing end that fall below a PHRED score of 30 [17]. K-mer identification software (https://github.com/phe-bioinformatics/kmerid) was used to compare the sequence reads with a panel of curated NCBI Reference Sequence Database genomes to identify the species. FASTQ reads from all sequences in this study (n = 790) were submitted to the European Nucleotide Archive (ENA) using the ena_submission tool (https://github.com/phe-bioinformatics/ena_submission) and can be found at the PHE Pathogens BioProject PRJEB18093 at ENA (http://www.ebi.ac.uk/ena/data/view/PRJEB18093; Additional file 2: Table S2).

**Reference strain analysis**
Ten GBS reference strains were sequenced and the genomic reads were assembled using SPAdes. The capsular locus sequences from all isolates were extracted using a BLAST query with the cps locus sequence of *Streptococcus agalactiae* strain A4 (accession number: DQ359707), a serotype V strain that covers the majority of the capsular genes [8, 18]. Artemis was used to annotate the capsular locus sequences [19]. Fastq reads (Accession numbers: ERS1462786 – ERS1462795) and annotated capsular locus sequences (Accession numbers: LT671983-LT671992; http://www.ebi.ac.uk/ena/data/view/LT671983-LT671992) for all reference strains are available in the PHE Pathogens BioProject PRJEB18093 at ENA (http://www.ebi.ac.uk/ena/data/view/PRJEB18093; Additional file 1: Table S1).

**De novo assembly**
Genomic reads were assembled using SPAdes (version 2.5.1) de novo assembly software [20] with the following parameters ‘spades.py –careful -1 strain.1.fastq.gz -2 strain.2.fastq -t 4 -k 33,55,77,85,93’. The resulting contigs.fasta file was converted into a BLAST database using blast + (version 2.2.27) [21] and queried using selected query sequence.

**Sequence alignment**
Capsular locus sequences were aligned using progressiveMauve [22] to visualise presence/absence of genes and define variable and conserved regions (Fig. 1). The cpsD-G conserved regions were also aligned using MEGA6 [23] to investigate single nucleotide polymorphisms (SNP).

**Bioinformatic analysis for serotype prediction**
Reads from each readset were mapped to a multi-fasta file containing the reference sequences using bowtie2 (version 2.1.0; following options used: –fr –minins 300 –maxins 1100 -k 99,999 -D 20 -R 3 -N 0 -L 20 -I S,1,0,50) [24]. A threshold coverage of >90% of the length of the sequence, minimum depth of 5 reads per bp and a mean depth of >20 reads over the entire length of the sequence was implemented during this step. SAMtools (version 0.1.19) [25] mpileup was used to detect non-reference positions (SNPs) in each readset. BAQ computation was disabled and anonymous read pairs were included in variant calling (option –B and –A). The mpileup file was parsed and SNPs were filtered based on base quality (>30) and number of reads (>5).

**Results**

**Selecting SNPs for serotype identification**
Serotype identification using PCR amplification followed by Sanger sequencing was previously described by Kong et al. for serotypes Ia to VII and later by Slotvet et al. to include serotype IX [26, 27]. These two publications identified 52 single nucleotide polymorphisms (SNP) and one repeat region within the conserved cpsD-G region and based upon their results were able to differentiate serotypes Ia to VII and IX. Serotype VIII was not included due to an inability to amplify the target region using the primers detailed in those studies.

In this study, we examined the previously described SNPs using the capsular locus sequences from 10 reference strains. The capsular operon regions covering genes *cpsD* up to the 5′ end of *cpsG* for nine serotypes were aligned
and all SNPs were recorded. Serotype VIII was excluded due to the lack of \(cpsF\) and \(cpsG\) genes; instead of the standard \(cpsD-cpsE-cpsF-cpsG-cpsH\) gene pattern, serotype VIII has \(cpsD-cpsE-cpsR-cpsH\) (Fig. 1).

Previously published variants were compared to the results of the reference strain capsular locus alignment and 47 SNPs and the repeat region were concordant between the two sets. The SNPs at positions 138, 198, 249, 1173 and 1527 were not found in the respective reference strains (Additional file 3: Table S3). Furthermore, based on the alignment of the reference strains, 11 novel SNPs were identified that differentiated the nine serotypes. These were added to the 48 published variants and the new set of 59 variants was validated using clinical isolates.

Isolates were prospectively sequenced as referred from hospital laboratories therefore, at this initial stage of the study, genomic data were available for only a limited number of isolates. In total, 28 isolates were included in the initial validation in addition to the 10 reference strains; 3-6 isolates were selected for each serotype, except serotypes VI and IX where only one clinical isolate had been sequenced and serotype VII where no representative clinical isolates had been received during that period (Additional file 4: Table S4). Following analysis, serotype-specific SNPs were confirmed in clinical isolates for all serotypes except serotype III which as previously described is subdivided into different subtypes [26]. To simplify the process, all SNPs present only in certain serotype III subtypes were removed \((n = 14)\), as well as the repeat region, leaving a final set of 44 SNPs (Table 1).

### Assessment of targets for molecular capsular typing

### Typeability

Firstly, the entire capsular locus was used as a target; reads were mapped to the capsular loci extracted from the 10 reference strains and serotype was assigned based on mapping coverage along the length of the reference sequence (mapping coverage >90%). Using this approach, a single serotype was assigned in 163 cases (20.6%) whereas in one case the highest percentage mapping coverage observed was below 90% resulting in a ‘Failed’ tag and in the remaining 629 cases the method was not able to distinguish between two serotypes that both exhibited >90% coverage. This result demonstrated higher than 90% similarity between the capsular sequences of serotypes Ia and III \((n = 535)\), IX and V \((n = 71)\) and IX and VII \((n = 17)\) (Additional file 5: Table S5). This was confirmed by aligning the two sequences within each pair using BLAST. The high similarity between Ia and III was also previously described by Chaffin et al. [28]. Contamination was suspected for the remaining four cases, each corresponding to different pairs, considering that the percent coverage seen using BLAST was <90%. The 167 cases where a serotype was assigned successfully, correspond mainly to five serotypes (Ib, \(n = 51\); II, \(n = 68\); IV, 305x80 Table 1 SNP sites used for identification of serotypes Ia-VII and XI in the conserved region, \(cpsD\) to 5' end of \(cpsG\)

| pos | Ia | Ib | II | III | IV | V | VI | VII | IX |
|-----|----|----|----|-----|----|---|----|-----|----|
| 62  | G  | A  | G  | A   | A  | A | G  | A   | A  |
| 211 | T  | T  | T  | T   | T  | G | T  | T   | T  |
| 218 | C  | C  | C  | C   | C  | T | C  | C   | C  |
| 240 | T  | T  | T  | T   | T  | T | C  | T   | T  |
| 327 | C  | C  | C  | C   | C  | C | C  | C   | T  |
| 419 | T  | C  | T  | T   | T  | T | T  | T   | T  |
| 429 | A  | T  | A  | T   | T  | T | A  | T   | T  |
| 437 | C  | C  | C  | C   | C  | C | C  | C   | T  |
| 457 | T  | A  | C  | A   | A  | A | C  | A   | A  |
| 466 | G  | G  | G  | G   | A  | G | G  | G   | G  |
| 486 | G  | A  | A  | A   | A  | A | A  | A   | A  |
| 551 | C  | C  | C  | C   | C  | C | C  | T   | T  |
| 606 | T  | T  | T  | T   | T  | C | T  | T   | T  |
| 627 | T  | C  | C  | C   | C  | C | C  | C   | C  |
| 645 | C  | T  | C  | T   | T  | T | C  | C   | C  |
| 803 | A  | A  | A  | A   | A  | A | A  | T   | A  |
| 1018| C  | C  | C  | C   | C  | C | C  | C   | A  |
| 1026| A  | G  | G  | G   | A  | G | G  | G   | G  |
| 1044| T  | T  | T  | T   | T  | C | T  | T   | T  |
| 1123| G  | G  | G  | G   | G  | G | G  | G   | A  |
| 1140| T  | T  | T  | T   | T  | T | C  | T   | C  |
| 1251| G  | G  | G  | G   | G  | A | G  | G   | G  |
| 1278| A  | A  | A  | A   | A  | G | A  | A   | A  |
| 1368| G  | G  | G  | G   | G  | G | G  | G   | A  |
| 1495| C  | C  | C  | C   | C  | C | A  | C   | C  |
| 1500| A  | G  | A  | A   | A  | A | A  | A   | A  |
| 1595| T  | C  | T  | T   | T  | C | T  | T   | T  |
| 1611| C  | C  | C  | C   | C  | C | T  | C   | C  |
| 1620| C  | C  | C  | C   | C  | C | T  | C   | C  |
| 1627| G  | G  | G  | G   | T  | G | G  | G   | T  |
| 1655| C  | T  | C  | C   | C  | C | C  | C   | C  |
| 1832| C  | C  | C  | T   | C  | C | C  | C   | C  |
| 1856| T  | C  | T  | T   | T  | T | T  | T   | T  |
| 1866| G  | G  | G  | G   | G  | G | G  | G   | A  |
| 1871| T  | T  | T  | T   | T  | C | T  | T   | T  |
| 1892| A  | A  | A  | A   | A  | G | A  | A   | A  |
| 1971| G  | G  | G  | G   | G  | G | A  | G   | G  |
| 2026| G  | A  | G  | G   | G  | G | G  | G   | G  |
| 2088| G  | G  | G  | G   | A  | G | G  | G   | G  |
| 2187| C  | C  | C  | C   | C  | C | G  | C   | C  |
| 2196| A  | A  | A  | A   | A  | A | G  | A   | A  |
| 2206| G  | G  | G  | G   | G  | G | G  | G   | A  |
| 2209| T  | T  | T  | T   | T  | T | C  | T   | T  |
| 2215| C  | C  | C  | C   | C  | C | T  | C   | T  |

Positions previously described [26, 27] are highlighted in green whereas SNPs identified in this study are highlighted in blue. SNPs highlighted in yellow are unique to a single serotype.
with the remaining two cases corresponding to samples assigned Ia and IX, respectively (Table 2). The serotypes corresponding to the respective pairs (Ia/III and IX/VII) were missed due to mapping coverage slightly below 90% (88.11% and 89.78%, respectively).

Secondly, SNPs within the conserved \( \text{cpsD-G} \) region were investigated amongst serotypes Ia-VII and IX. The reads were first mapped to the full capsule and any isolates with serotype VIII capsule were precluded from further analysis (\( n = 2 \)). Reads were mapped to the \( \text{cpsD-G} \) region of \( S. \text{agalactiae} \) strain 3139 (region 3166-5955: accession number AF332908.1) and a serotype was assigned based on the bases present in the 44 SNP positions described above (Table 1). Using this approach, serotype was assigned to 749 cases (94.8%) whereas in the remaining 39 cases, serotype was not assigned due to either low base mapping (\( n = 17 \)), a mixed base (variant present in 20-80% of the reads) in certain SNP positions (\( n = 2 \)) or an incomplete SNP profile match (\( n = 20 \)) (Additional file 6: Table S6). In two cases no SNPs were detected; one of the isolates had also failed with the previous method with a high percent coverage of 71.93% whereas the second isolate was the Ia isolate called as a single serotype by the previous method. Further investigation, revealed that the failed isolate, when mapped to the full capsular locus reference file, had no reads mapping in the region corresponding to the 3′end of \( \text{cpsC} – \text{cpsH} \) inclusive. Similar investigation for the Ia isolate revealed a smaller region of no coverage within the \( \text{cpsD-G} \) region (1549-2069 bps), which covered 12 of the 44 SNP positions. Due to the low coverage (<90%) the SNP analysis was not performed. However, based on the 32 SNP positions that were covered this isolate matched (32/32) the serotype Ia SNP profile.

The variable region \( \text{cpsG-K} \) (Fig. 1) was the third and final region to be evaluated in this study. This region was previously successfully used to assign serotype from WGS data using de novo assembly followed by BLAST analysis [16]. In this study, a mapping approach was used with the \( \text{cpsG-K} \) regions extracted from the capsular locus sequences of the 10 reference strains used as a reference. This approach assigned a serotype to 789 of the isolates (99.9%) and the one isolate that failed with highest coverage of 66.97% was the same isolate that failed with the two previous methods.

### Concordance

Concordance of the three molecular serotyping assays was observed compared to the latex agglutination method. Concordance was observed in 120 of the 162 typed isolates (74.1%) using the full capsular locus approach (Table 3). The 42 discordant isolates were investigated by repeat serotyping and/or WGS. In 22 cases, discordances were resolved; in seven cases repeat WGS was concordant with the serotype whereas in the remaining 15 cases repeating the serological analysis gave a result concordant with the WGS. The one failed isolate mentioned previously was also investigated; originally typed serologically as serotype VI, repeat serological analysis was not able to assign a serotype due to auto-agglutination with all sera.

The SNP-based approach resulted in concordance with serology for 653 of 749 typed isolates (87.2%). The remaining 96 discordant isolates were investigated by repeating serology and/or WGS. Discordance was resolved in 67 cases; in 29 cases repeat WGS was concordant with the laboratory serotype whereas in the remaining 37 cases repeating the serological analysis gave a result
| SampleID    | cpsG-K | Full CPS | SNP-based SNPhits | Original Results | Retested lab | Retested WGS | Resolved |
|-------------|--------|----------|-------------------|------------------|--------------|--------------|----------|
| PHEGBS0002  | II     | II       | Serum type         | n = 42/44         | IX           | FALSE        | FALSE    | NT       | NT       | No       |
|             |        |          |                    |                  |              |              |          |          |          |          |
| PHEGBS0007  | la     | la,II    | Serum type          | n = 44/44        | IX           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0016  | II     | II       | Serum type          | n = 44/44        | IX           | FALSE        | FALSE    | FALSE    | lb       | II       | No       |
| PHEGBS0017  | V      | V,IX     | Serum type          | n = 44/44        | VI           | FALSE        | NT        | FALSE    | NT       | No       |
| PHEGBS0022  | V      | V,IX     | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | NT       | No       |
| PHEGBS0024  | la     | la,II    | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0025  | la     | la,II    | Serum type          | n = 44/44        | IX           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0026  | la     | la,II    | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0027  | la     | la,II    | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0028  | II     | II       | Serum type          | n = 44/44        | VIII         | FALSE        | FALSE    | FALSE    | la       | II       | No       |
| PHEGBS0029  | lb     | lb       | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | lb       | Yes      |
| PHEGBS0030  | V      | V,IX     | Serum type          | n = 44/44        | VIII         | FALSE        | NT        | FALSE    | NT       | No       |
| PHEGBS0033  | V      | V,IX     | Serum type          | n = 44/44        | VI           | FALSE        | NT        | FALSE    | NT       | No       |
| PHEGBS0035  | la     | la       | Serum type          | n = 0/44         | NT           | FALSE        | FALSE    | NT       | la       | Yes      |
| PHEGBS0037  | VI     | VI       | Serum type          | n = 44/44        | III          | FALSE        | FALSE    | FALSE    | VI       | Yes      |
| PHEGBS0043  | la     | la,II    | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0070  | la     | la,II    | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0075  | II     | II       | Serum type          | n = 44/44        | NT           | FALSE        | FALSE    | FALSE    | II       | Yes      |
| PHEGBS0082  | V      | V,IX     | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | V        | Yes      |
| PHEGBS0089  | V      | V,IX     | Serum type          | n = 44/44        | Ib           | FALSE        | FALSE    | FALSE    | IV       | Yes      |
| PHEGBS0086  | la     | la,II    | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0091  | II     | II       | Serum type          | n = 44/44        | NT           | FALSE        | FALSE    | FALSE    | la       | II       | No       |
| PHEGBS0098  | V      | V,IX     | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | V        | Yes      |
| PHEGBS0103  | IV     | IV       | Serum type          | n = 44/44        | Ib           | FALSE        | FALSE    | FALSE    | IV       | Yes      |
| PHEGBS0134  | la     | la,II    | Serum type          | n = 44/44        | IV           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0152  | la     | la,II    | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | la       | Yes      |
| PHEGBS0157  | IV     | IV,III   | Serum type          | n = 44/44        | Ib           | FALSE        | NT        | FALSE    | IV       | Yes      |
| PHEGBS0163  | II     | II       | Serum type          | n = 42/44        | Ib           | FALSE        | NT        | FALSE    | la       | II       | No       |
| PHEGBS0167  | III    | III,la   | Serum type          | n = 44/44        | NT           | FALSE        | NT        | FALSE    | III      | Yes      |
| PHEGBS0176  | III    | III,la   | Serum type          | n = 42/44        | V            | FALSE        | NT        | NT       | NT       | No       |
| PHEGBS0195  | la     | la,II    | Serum type          | n = 44/44        | III          | FALSE        | NT        | FALSE    | III      | III      | Yes      |
| PHEGBS0196  | la     | la,II    | Serum type          | n = 44/44        | Ib           | FALSE        | NT        | FALSE    | lb       | lb       | Yes      |
| PHEGBS0198  | lb     | lb       | Serum type          | n = 44/44        | V            | FALSE        | FALSE    | FALSE    | V        | V        | Yes      |
| PHEGBS0200  | V      | V,IX     | Serum type          | n = 44/44        | la           | FALSE        | NT        | FALSE    | la       | la       | Yes      |
| PHEGBS0201  | III    | III,la   | Serum type          | n = 44/44        | la           | FALSE        | NT        | FALSE    | la       | la       | Yes      |
| PHEGBS0203  | la     | la,II    | Serum type          | n = 44/44        | V            | FALSE        | NT        | FALSE    | V        | V        | Yes      |
| PHEGBS0204  | la     | la,II    | Serum type          | n = 44/44        | III          | FALSE        | NT        | FALSE    | III      | III      | Yes      |
| PHEGBS0205  | V      | V,IX     | Serum type          | n = 44/44        | III          | FALSE        | NT        | FALSE    | III      | III      | Yes      |
| PHEGBS0208  | IV     | IV       | Serum type          | n = 44/44        | V            | FALSE        | FALSE    | FALSE    | V        | V        | Yes      |
| PHEGBS0209  | III    | III,la   | Serum type          | n = 44/44        | la           | FALSE        | NT        | FALSE    | la       | la       | Yes      |
| PHEGBS0210  | V      | V,IX     | Serum type          | n = 44/44        | la           | FALSE        | NT        | FALSE    | la       | la       | Yes      |
| Isolate Code | Serotype | NT | V | VI | VJ | IX | True Serotype | Concordance |
|--------------|----------|----|---|----|----|----|----------------|-------------|
| PHEGBS0211   | IaIaIa   | n = 44/44 | III | FALSE | NT | FALSE | III | III | Yes |
| PHEGBS0212   | IaIaIa   | n = 44/44 | III | FALSE | NT | FALSE | III | III | Yes |
| PHEGBS0215   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0216   | IIIIa    | n = 42/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0217   | IaIaIa   | n = 44/44 | III | FALSE | NT | FALSE | III | III | Yes |
| PHEGBS0218   | IbIbIb   | n = 44/44 | III | FALSE | FALSE | FALSE | Ia  | Ia  | Yes |
| PHEGBS0220   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0222   | IbIbIb   | n = 44/44 | III | FALSE | FALSE | FALSE | III | III | Yes |
| PHEGBS0225   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0227   | IaIaIa   | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0228   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0229   | IbIbIb   | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0231   | VVJIX    | n = 44/44 | III | FALSE | NT | FALSE | III | III | Yes |
| PHEGBS0232   | IaIaIa   | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0233   | IVIV     | n = 44/44 | III | FALSE | FALSE | FALSE | III | III | Yes |
| PHEGBS0236   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0238   | IbIbIb   | n = 44/44 | III | FALSE | FALSE | FALSE | III | III | Yes |
| PHEGBS0240   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0241   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0242   | IaIaIa   | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0264   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | NT  | III | Yes |
| PHEGBS0266   | IVIV     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0271   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | II  | Yes |
| PHEGBS0313   | IVIV     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0327   | IVIV     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0352   | IIII     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | Yes |
| PHEGBS0373   | VVJIX    | n = 44/44 | NT  | FALSE | NT | FALSE | NT  | V   | No  |
| PHEGBS0390   | IIII     | n = 44/44 | V   | FALSE | FALSE | FALSE | V   | II  | No  |
| PHEGBS0394   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | II  | Yes |
| PHEGBS0398   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | V   | II  | No  |
| PHEGBS0404   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | NT  | II  | No  |
| PHEGBS0432   | IIII     | n = 44/44 | V   | FALSE | FALSE | FALSE | NT  | No  |
| PHEGBS0433   | IVIV     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | No  |
| PHEGBS0460   | IaIaIa   | n = 44/44 | III | FALSE | NT | FALSE | III | III | Yes |
| PHEGBS0492   | IIIIa    | n = 44/44 | NT  | FALSE | NT | FALSE | III | Yes |
| PHEGBS0520   | VVJIX    | n = 44/44 | NT  | FALSE | NT | FALSE | III | Yes |
| PHEGBS0554   | IIII     | n = 44/44 | NT  | FALSE | FALSE | FALSE | NT  | No  |
| PHEGBS0568   | IIII     | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | No  |
| PHEGBS0586   | IIII     | n = 44/44 | V   | FALSE | FALSE | FALSE | NT  | No  |
| PHEGBS0600   | IIII     | n = 41/44 | III | FALSE | NT | FALSE | NT  | No  |
| PHEGBS0603   | IIIIa    | n = 44/44 | NT  | FALSE | NT | FALSE | NT  | No  |
| PHEGBS0607   | VIIIIIX  | n = 44/44 | III | FALSE | NT | FALSE | III | No  |
| PHEGBS0610   | IIIIa    | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | No  |
| PHEGBS0611   | IaIaIa   | n = 44/44 | Ia  | FALSE | NT | FALSE | Ia  | Ia  | No  |
concordant with the WGS. Of the 96 discordant isolates, 37 were also discordant with the previous method; the remaining five were non-typeable by the SNP-based method (Table 3).

Finally, using the variable $cpsG-K$ region concordance was observed in 684 of the 789 cases (86.7%). The remaining 105 discordant isolates, included all discordant isolates from the first method ($n = 42$) and 95/96 of the discordant isolates from the second method, in addition to 10 non-typeable by the SNP-based method. All discordant isolates were retested with latex agglutination by an investigator blinded to the previous results. One isolate discordant with the SNP-based method was correctly assigned serotype Ia with the $cpsG-K$ method; using the full capsule method the serotype pair Ia/III was called and with the SNP-based method serotype III; following retesting in the laboratory serotype V was assigned which did not agree with either method. Further investigation into this isolate, using mapping analysis and de novo assembly followed by BLAST analysis, revealed that whereas the $cpsD-G$ region corresponded to serotype III (44/44 SNP matches) this isolate contained a serotype Ia $cpsH$ gene [28], suggesting a recombination event may have taken place. The serological method was repeated for all discordant isolates ($n = 105$) and in 40 cases the new result corresponded to the predicted serotype (by WGS) whereas in 20 cases no serotype was assigned due to lack of reaction or reaction with multiple sera. Of the remaining 45 discordant cases, 44 were re-sequenced and in 31 of these cases the new predicted serotype was concordant with the serological result. Overall following retesting only 14 cases remain truly discordant excluding the 20 non-typeable by sera (Table 3).

**Comparison of mapping and assembly approach**

The results of the third mapping-approach, that uses the variable $cpsG-K$ region, were compared to the previously described assembly method followed by BLAST [16]. All 790 isolates were assembled and serotype was assigned following BLAST analysis of the contigs against the variable $cpsG-K$ region from all 10 serotypes. The results of this approach were concordant with the results from the mapping approach for 721/790 isolates (Additional file 2: Table S2). One isolate that had previously failed with the mapping approach, with all three methods, due to low coverage of the capsular operon region (depth $\geq 5$ is used as threshold) return no hits with BLAST. Serotype was not assigned for the remaining 68 isolates due to lack of a complete match; the $cpsG-K$ region was present but split into two or more contigs. Further investigation in a subset of these cases ($n = 20$) revealed that in all cases the

| Isolate   | Serotype 1 | Serotype 2 | Serotype 3 | Depth |
|-----------|------------|------------|------------|-------|
| PHEGBS0615 | la         | Ia,III     | Ia         | V     |
| PHEGBS0620 | la         | Ia,III     | Serotype undetermined | n = 44/44 |
| PHEGBS0627 | II         | II         | II         | n = 44/44 |
| PHEGBS0640 | III,la     | III        | III        | n = 44/44 |
| PHEGBS0641 | III,la     | III        | NT         | n = 44/44 |
| PHEGBS0642 | III,la     | III        | la         | n = 44/44 |
| PHEGBS0643 | III,la     | III        | NT         | n = 44/44 |
| PHEGBS0644 | III,la     | III        | NT         | n = 44/44 |
| PHEGBS0671 | IV         | IV         | Serotype undetermined | n = 38/44 |
| PHEGBS0728 | II         | II         | NT         | n = 44/44 |
| PHEGBS0737 | II         | II         | V          | n = 44/44 |
| PHEGBS0761 | V          | V          | Serotype undetermined | n = 42/44 |
| PHEGBS0772 | la         | Ia,III     | Serotype undetermined | n = 38/44 |
| PHEGBS0821 | VI         | VI         | NT         | n = 44/44 |
| PHEGBS0822 | Ia         | Ia         | NT         | n = 44/44 |
| PHEGBS0823 | la         | Ia         | NT         | n = 44/44 |
| PHEGBS0824 | Ia         | Ia         | la         | n = 44/44 |
| PHEGBS0825 | VII        | VII        | VII        | n = 44/44 |
| PHEGBS0826 | VI         | VI         | la         | n = 44/44 |
serotype assigned by mapping was also the serotype with the highest coverage along the multiple contigs in the assembly/BLAST approach.

Discussion

The conserved region cpsD-G was previously used for molecular capsular typing in Group B streptococci using a SNP-based approach with PCR amplification and Sanger sequencing [26, 27], whereas more recently the variable region cpsG-K was used to predict serotype from WGS data using a de novo assembly and BLAST analysis approach [16]. In this study, these two capsular locus target regions as well as the full capsular locus sequence were investigated for their efficacy in predicting serotype in GBS from WGS data. We used a mapping approach followed by SNP-based approach for the cpsD-G region on a validation panel of 790 GBS isolates.

The full capsular locus approach was able to predict 5/10 serotypes (Ib, II, IV, VI, VIII) with distinct capsular locus sequences but was unable to distinguish the remaining five, including serotype III which is the most prevalent serotype in the UK. These latter serotypes were resolved to one of two highly similar capsular loci (Ia/III, V/IX, VII/IX) each sharing more than 90% similarity. Previous publications have reported the similarity of the serotype Ia and III capsular loci; the main difference lies in the cpsH gene [28]. Further investigation into the three serotypes (V, VII & IX) of the remaining two pairs (V/IX & VII/IX) showed high sequence variability for cpsM based on the read mapping patterns for serotypes V and IX; that is in addition to the presence of cpsN in serotype V (V: cpsG-cpsH-cpsM-cpsN-cpsO-cpsI-cpsK; IX: cpsG-cpsH-cpsM-cpsO-cpsI-cpsK). For the VII/IX pair, the two serotypes differ in the presence of cpsO in serotype IX and cpsI in VII (VII: cpsG-cpsH-cpsM-cpsI-cpsJ-cpsK). Furthermore, fragmented mapping (reads mapping to some region but not others) between cpsM and cpsK suggests high sequence variability in cpsJ as well. The SNP-based approach failed to predict a serotype in 39 cases due to low mapping coverage or a mixed base at certain SNP positions for approximately half the cases; this dependence on specific positions is one of the disadvantages of using a SNP-based methodology coupled with mapping and strict quality criteria (depth ≥ 5 and base quality ≥ 30). However, the remaining unassigned cases were of particular concern; in these cases failure to predict serotype was due to a mixed SNP profile, this is a 41-43/44 match to a serotype-specific SNP profile with one to three SNP positions matching the expected base of another serotype. The positions affected include 12 SNPs located in cpsE and cpsF, including 10 previously published (419, 429, 437, 457, 486, 645, 1026, 1611, 1627 and 1866). However, based on previous studies [26], three of these positions have alternative variants in serotype III subtypes. Specifically, at position 437, the presence of a T instead of a C is the only difference between serotype II and III-4 SNP profiles of region cpsD-G; three isolates have 43/44 SNPs matching the serotype II SNP profile and a T in position 437 suggesting that these isolates are indeed serotype III subtype 4 which also agrees with the serological result and the result from the cpsG-K method. Furthermore, in positions 486 and 1026 the presence of G and A instead of A and G, respectively are indicative of serotype III subtype 3 and based on this, three isolates with a partial 42/44 serotype III profile and G and A in 486 and 1026 respectively would be assigned serotype III subtype 3. This also agrees with the cpsG-K assignment and in one of the cases with the serological result. For the remaining 7 positions, the presence of these alternate variants, even though occurring rarely, suggests that variants at these positions are not conserved within a serotype.

Finally, mapping the reads to the variable cpsG-K region produced the highest typeability (99.9%) with only a single isolate remaining non-typeable. However, this isolate was non-typeable with all methods and was shown to lack a large part of the capsular locus (cpsC-H) therefore the lack of serotype prediction was correct. Using this method 86.7% concordance was observed with only 105 isolates, which included all (but one) of the discordant isolates from the two previous methods and 10 non-typeable isolates by the SNP method. Therefore, this number represents the discordance between the molecular and serological approach. Following retesting using both serological and WGS methods only 14 isolates remained truly discordant.

The initially high discordance rate can mainly be attributed to the traditional methodology of latex agglutination which can be subjective; specifically re-serotyping using latex agglutination resulted in the same serotype in only 39/105 cases indicating latex agglutination or lab transcription error. This high ambiguity with the serological method may be in part due to a problem with a particular batch as some of the sera used were shown to agglutinate poorly when tested with controls. This included the Ia sera resulting in a number of serotype Ia isolates (n = 18) being mis-identified as rarer types or non-typeables and was resolved when a new batch was used. Furthermore, isolates referred to the reference lab are inoculated onto an agar plate and following overnight incubation a sweep of material is usually tested for serotyping whereas for retesting subculture from a single colony was used. Therefore the presence of a mixed population in the initial culture could result in ambiguous serotyping results downstream in the investigation. However not all discordance can be attributed to the traditional methodology. Cases where the traditional re-serotyping was consistent but repeat WGS resulted in a different serotype could be attributed to a laboratory transcription error.
Overall, this study demonstrated that molecular capsular typing using WGS is a viable alternative to the traditional serotyping method and the most efficient method between the three investigated was using a mapping approach on the variable *cpsG-K* method. These results further support the evidence provided by Sheppard et al. [16], however, unlike the assembly-based methodology used in that study, a mapping approach as described here is more appropriate for use in reference microbiology. Generally, mapping is faster and can provide more precise, region-specific, quality metrics than genome assembly. Furthermore, comparisons of the two approaches, revealed lower typeability with the assembly approach followed by blasting (721/790 vs 789/790 with the mapping approach) due to incomplete assembly of the capsular operon region.

**Conclusions**

The use of genomics to determine serotype of GBS is critical to Public Health, improving on current subjective methodologies, enabling determination of serotype in strains that were previously designated nontypeable using phenotypic testing. Ultimately it will enable testing, remote determination of serotype and collation of data from strains without reliance of specialised testing centres. The ability to determine the serotype is essential to enable identification of cross infections linked to healthcare associated infection and monitoring of specific serotypes in differing patient groups. It will have increasing importance when considering the serological profile of the bacterial population in response to forthcoming vaccinations.

**Additional files**

Additional file 1: Table S1. Information on historical GBS strains used as reference for the 10 serotypes (Ia-IX). (XLSX 11 kb)

Additional file 2: Table S2. Metadata for all clinical isolates used in this study (n = 790). (XLSX 36 kb)

Additional file 3: Table S3. Investigation of the previously published SNPs using the 10 reference strains. SNPs highlighted in yellow do not correlate with the respective reference and are removed from subsequent analysis. (XLSX 19 kb)

Additional file 4: Table S4. Investigation of the SNPs (previously published and novel) identified using multiple alignment of the reference *cps* loci using a small a small dataset of clinical samples (n = 28). SNP positions highlighted in grey represent SNPs not found in all isolates of a particular serotype. These positions were removed and the remaining SNPs represent the final set used in this study. (XLSX 23 kb)

Additional file 5: Table S5. Sequence analysis for the serotype pairs identified using the full *cps* locus approach. Hit coverage corresponds to the mapping coverage observed during analysis whereas the BLAST coverage corresponds to the percent coverage seen during pairwise alignment using BLAST. (XLSX 8 kb)

Additional file 6: Table S6. Investigation of the not-typeable ("Serotype underdetermined") isolates from the SNP-based approach. The pileup file created during the analysis was investigated in detail to determine the serotology behind the incomplete SNP profiles. (XLSX 19 kb)

**Abbreviations**

ENA: European Nucleotide Archive; GBS: Group B streptococcus; PCR: Polymerase chain reaction; PHE: Public Health England; SNP: Single nucleotide polymorphism; WGS: Whole genome sequencing

**Acknowledgements**

The authors would like to acknowledge Roger Daniel, Chenchal Dhami and MacDonald Prest for performing culture, latex agglutination based serotyping and DNA extraction. Whole genome sequencing was performed by Catherine Arnold and the team in Genome Services and Development Unit, PHE Colindale. Special thanks to Rajesh Radhakrishnan for his help with the ENA submissions. Finally, we would like to thank all scientists and microbiologists for referral of strains to the reference laboratory.

**Funding**

No funding was received.

**Availability of data and materials**

The datasets generated and analysed during the current study are available in the European Nucleotide Archive (ENA), http://www.ebi.ac.uk/ena/data/view/PRJEB18093. All data analysed during this study are included in this published article and its additional files.

**Authors’ contributions**

GK performed the bioinformatics analysis, contributed to the interpretation of the data and drafted the manuscript. DP was involved in the collection of the isolates, contributed to latex agglutination and DNA extraction for the isolates in this study and contributed to the interpretation of the data and writing of the manuscript. AE and VJC revised the manuscript and jointly supervised the work. All authors read and approved the final manuscript.

**Competing interests**

The authors declare they have no competing interests.

**Consent for publication**

Not applicable. The study does not include any individual person’s data.

**Ethics approval and consent to participate**

Not applicable.

**Author details**

1Respiratory and Vaccine Preventable Bacterial Reference Unit, Public Health England, London, UK. 2Microbiology Reference Division, Public Health England, London, UK.

Received: 15 December 2016 Accepted: 25 May 2017

**References**

1. Le Doan K, Heath PT. An overview of global GBS epidemiology. Vaccine. 2013;31:5D7–D12.
2. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis. 2009;49:985–92.
3. Bekker V, Bijlsma MW, van de Beek D, Kuipers TW, Van der Ende A. Incidence of invasive group B streptococcal disease and pathogen genotype distribution in newborn babies in the Netherlands over 25 years: a nationwide surveillance study. Lancet Infect Dis. 2014;14:1083–9.
4. Bedford H, De Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. Br Med J. 2001;323:1–5.
5. Madhi SA, Cutland CL, Jose L, Koen A, Govender N, Wittert F, et al. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016;16:293–34.
6. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev. 1998;11:497–513.
7. Martins ER, Pessanha MA, Ramirez M, Melo-Cristino J. Portuguese Group for the Study of Streptococcal Infections and the PG for the S of S. Analysis of group B streptococcal isolates from infants and pregnant women in...
Portugal revealing two lineages with enhanced invasiveness. J Clin Microbiol. 2007;45:3224–9.

8. Cieslewicz MJ, Chaffin D, Gusman G, Kasper D, Madan A, Rodrigues S, et al. Structural and genetic diversity of group B streptococcus capsular polysaccharides. Infect Immun. 2005;73:3096–103.

9. Arakere G, Flores AE, Ferrieri P, Frasch CE. Inhibition enzyme-linked immunosorbent assay for serotyping of group B streptococcal isolates. J Clin Microbiol. 1999;37:2564–7.

10. Slotved H, Elliott J, Thompson T, Konradsen HB. Latex assay for serotyping of group B streptococcus isolates latex assay for serotyping of group B streptococci. J Clin Microbiol. 2003;41:4445–7.

11. Rosini R, Campisi E, De Chiara M, Tettelin H, Rinaudo D, Toniolo C, et al. Genomic analysis reveals the molecular basis for capsule loss in the group B streptococcus population. PLoS One. 2015;10:e0125985.

12. Sellin M, Olofsson C, Hakansson S, Norgren M. Genotyping of the capsule gene cluster (cps) in nontypeable group B streptococci reveals two major cps allelic variants of serotypes III and VII. J Clin Microbiol. 2000;38:3420–8.

13. Borchardt SM, Foxman B, Chaffin DO, Rubens CE, Tallman PA, Manning SD, et al. Comparison of DNA dot blot hybridization and Lancefield capillary precipitin methods for group B streptococcal capsular typing Comparison of DNA dot blot hybridization and Lancefield capillary precipitin methods for group B streptococcal capsular typing. J Clin Microbiol. 2004;42:146–50.

14. Yao K, Poulsen K, Maione D, Rinaudo CD, Baldassarri L, Telford JL, Sørensen UB, Members of the DEVANI Study Group M of the DS, Kilian M. Capsular gene typing of Streptococcus agalactiae compared to serotyping by latex agglutination. J Clin Microbiol 2013, 51:503–507.

15. Breeding KM, Ragipani B, Lee K-UD, Malik M, Randis TM, Ratner AJ, et al. Real-time PCR-based serotyping of Streptococcus agalactiae. Nat Sci Rep. 2016;6:38523.

16. Sheppard AE, Vaughan A, Jones N, Turner P, Turner C, Efstratiou A, et al. Capsular typing method for Streptococcus agalactiae using whole genome sequence data. J Clin Microbiol. 2016;54:1388–90.

17. Bolger AM, Lohse M, Usadel B. Trimomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.

18. Berti F, Campisi E, Toniolo C, Morelli L, Crotti S, Rosini R, et al. Structure of the type IX group B streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII. J Biol Chem. 2014;289:23437–48.

19. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, et al. Artemis: sequence visualization and annotation. Bioinformatics. 2000;16:944–5.

20. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77.

21. Darling AE, Mau B, Perna NT. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS One. 2010;5:e11147.

22. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013;30:2725–9.

23. Langmead B, Salzberg S. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.

24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25:2078–9.

25. Kong F, Gowans S, Martin D, James G, Gilbert GL. Serotype identification of group B streptococci by PCR and sequencing. J Clin Microbiol. 2002;40:216–26.

26. Slotved HC, Kong F, Lamberts L, Sauer S, Gilbert GL. Serotype IX, a proposed new Streptococcus agalactiae serotype. J Clin Microbiol. 2007;45:2929–36.

27. Chaffin DO, Beres SB, Yim HH, Rubens CE. The serotype of type IIa and III group B streptococci is determined by the polymerase gene within the polycistronic capsular operon the serotype of type IIa and III group B streptococci is determined by the polymerase gene within the polycistronic capsule op. J Bacteriol. 2000;182:4466–77.